SG11201909793YA - AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS - Google Patents

AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS

Info

Publication number
SG11201909793YA
SG11201909793YA SG11201909793YA SG11201909793YA SG 11201909793Y A SG11201909793Y A SG 11201909793YA SG 11201909793Y A SG11201909793Y A SG 11201909793YA SG 11201909793Y A SG11201909793Y A SG 11201909793YA
Authority
SG
Singapore
Prior art keywords
shi
meieki
nagoya
aichi
international
Prior art date
Application number
Other languages
English (en)
Inventor
Tatsuya Yamagishi
Mikio Morita
Yuji Shishido
Ryuichi Yamaguchi
Norikazu Gaja
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of SG11201909793YA publication Critical patent/SG11201909793YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201909793Y 2017-06-20 2018-06-20 AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS SG11201909793YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762522215P 2017-06-20 2017-06-20
PCT/JP2018/023412 WO2018235851A1 (en) 2017-06-20 2018-06-20 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS

Publications (1)

Publication Number Publication Date
SG11201909793YA true SG11201909793YA (en) 2019-11-28

Family

ID=64735688

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909793Y SG11201909793YA (en) 2017-06-20 2018-06-20 AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS

Country Status (21)

Country Link
US (1) US11154544B2 (ja)
EP (1) EP3487839B1 (ja)
JP (1) JP6592702B1 (ja)
KR (1) KR102577137B1 (ja)
CN (1) CN110612285B (ja)
AU (1) AU2018289731B2 (ja)
BR (1) BR112019021736A2 (ja)
CA (1) CA3059687A1 (ja)
DK (1) DK3487839T3 (ja)
ES (1) ES2851004T3 (ja)
HU (1) HUE053460T2 (ja)
MX (1) MX2019012635A (ja)
MY (1) MY200962A (ja)
PH (1) PH12019502850A1 (ja)
PL (1) PL3487839T3 (ja)
PT (1) PT3487839T (ja)
RU (1) RU2768149C2 (ja)
SG (1) SG11201909793YA (ja)
TW (1) TWI769266B (ja)
WO (1) WO2018235851A1 (ja)
ZA (1) ZA201906888B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008995A2 (pt) * 2018-12-26 2021-08-10 Raqualia Pharma Inc. derivados heterocíclicos como bloqueadores de nav1.7 e nav1.8
CN114073698B (zh) 2020-08-20 2023-03-31 山西泰睿鑫科技有限公司 一种止痛止痒药物组合物及其应用方法
CN111920796A (zh) * 2020-08-28 2020-11-13 南京医科大学 化合物在制备治疗癫痫药物中的应用
AR126669A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
AR126670A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
WO2024159284A1 (pt) * 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Hidrazidas bloqueadoras de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits
WO2024159287A1 (pt) * 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Hidroxamatos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits
WO2024159288A1 (pt) * 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Amidas bloqueadoras de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1809271E (pt) * 2004-09-10 2010-08-30 Newron Pharm Spa Utilização de (halogenobenziloxi)benzilamino-propanamidas para o fabrico de medicamentos activos como moduladores selectivos dos canais de sódio e/ou de cálcio
BRPI0516915A (pt) * 2004-12-01 2008-03-11 Devgen Nv derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
EP2044055A4 (en) * 2006-07-21 2011-03-23 Takeda Pharmaceutical amide compounds
WO2009132454A1 (en) 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Di-t-butylphenyl piperazines as calcium channel blockers
KR20110022089A (ko) * 2008-06-27 2011-03-04 노파르티스 아게 유기 화합물
MX2011012712A (es) * 2009-05-29 2012-01-30 Raqualia Pharma Inc Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
CN103249721B (zh) * 2010-10-18 2016-10-12 拉夸里亚创药株式会社 作为ttx-s阻滞剂的芳胺衍生物
WO2013000651A1 (en) * 2011-06-27 2013-01-03 Newron Pharmaceuticals S.P.A. Fluorinated arylalkylaminocarboxamide derivatives
EP2841421B1 (en) * 2012-04-25 2019-06-05 RaQualia Pharma Inc Amide derivatives as ttx-s blockers
CA2887887C (en) 2012-10-31 2020-08-25 Raqualia Pharma Inc. Pyrazolopyridine derivatives as ttx-s blockers
EP2730570A1 (de) * 2012-11-13 2014-05-14 Bayer CropScience AG Pyridyloxyalkylcarboxamide und deren Verwendung als Endoparasitizide und Nematizide
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
CA2929502A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Substituted pyridine derivatives useful as gsk-3 inhibitors
WO2015144657A1 (en) * 2014-03-27 2015-10-01 Bayer Cropscience Ag Use of pyridyloxyalkylcarboxamides for the control of unwanted microorganisms
EP3325446A1 (de) * 2015-07-17 2018-05-30 Bayer CropScience Aktiengesellschaft Substituierte aryl- und heteroarylcarbonsäurehydrazide oder deren salze und ihre verwendung zur steigerung der stresstoleranz in pflanzen

Also Published As

Publication number Publication date
RU2019133530A3 (ja) 2021-08-04
PT3487839T (pt) 2021-02-11
KR20200015888A (ko) 2020-02-13
DK3487839T3 (da) 2021-01-18
CA3059687A1 (en) 2018-12-27
WO2018235851A1 (en) 2018-12-27
RU2019133530A (ru) 2021-07-20
EP3487839B1 (en) 2020-12-23
AU2018289731A1 (en) 2019-11-14
TW201904944A (zh) 2019-02-01
US11154544B2 (en) 2021-10-26
ES2851004T3 (es) 2021-09-02
US20200016135A1 (en) 2020-01-16
BR112019021736A2 (pt) 2020-05-05
ZA201906888B (en) 2021-02-24
JP6592702B1 (ja) 2019-10-23
JP2019532911A (ja) 2019-11-14
HUE053460T2 (hu) 2021-06-28
MX2019012635A (es) 2019-12-11
TWI769266B (zh) 2022-07-01
AU2018289731B2 (en) 2021-11-18
CN110612285B (zh) 2023-04-04
EP3487839A1 (en) 2019-05-29
KR102577137B1 (ko) 2023-09-11
RU2768149C2 (ru) 2022-03-23
MY200962A (en) 2024-01-26
PH12019502850A1 (en) 2020-09-28
EP3487839A4 (en) 2020-03-18
PL3487839T3 (pl) 2021-06-14
CN110612285A (zh) 2019-12-24

Similar Documents

Publication Publication Date Title
SG11201909793YA (en) AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201909325RA (en) 2-amino-quinoline derivatives
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11202000266VA (en) Quinoline derivatives for treating infections with helminths
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201909245PA (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201408617PA (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201901817SA (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
SG11201809537VA (en) Urea motif containing compounds and derivatives thereof as antibacterial drugs
SG11201903348UA (en) Therapeutic compounds and methods of use thereof
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201906543RA (en) HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY
SG11201908226XA (en) Rapamycin analog